RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Lineage Cell Therapeutics Stock

Lineage Cell Therapeutics P/S 2024

Lineage Cell Therapeutics P/S

33.08

Ticker

LCTX

ISIN

US53566P1093

WKN

A2PP89

As of Oct 12, 2024, Lineage Cell Therapeutics's P/S ratio stood at 33.08, a 33.87% change from the 24.71 P/S ratio recorded in the previous year.

The Lineage Cell Therapeutics P/S history

Lineage Cell Therapeutics Aktienanalyse

What does Lineage Cell Therapeutics do?

Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Lineage Cell Therapeutics's P/S Ratio

Lineage Cell Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Lineage Cell Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Lineage Cell Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Lineage Cell Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Lineage Cell Therapeutics stock

What is the price-to-earnings ratio of Lineage Cell Therapeutics?

The price-earnings ratio of Lineage Cell Therapeutics is currently 33.08.

How has the price-earnings ratio of Lineage Cell Therapeutics changed compared to last year?

The price-to-earnings ratio of Lineage Cell Therapeutics has increased by 33.87% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Lineage Cell Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Lineage Cell Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Lineage Cell Therapeutics affect the company?

An increase in the price-earnings ratio of Lineage Cell Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Lineage Cell Therapeutics affect the company?

A decrease in the price-earnings ratio of Lineage Cell Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Lineage Cell Therapeutics?

Some factors that influence the price-earnings ratio of Lineage Cell Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Lineage Cell Therapeutics pay?

Over the past 12 months, Lineage Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lineage Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Lineage Cell Therapeutics?

The current dividend yield of Lineage Cell Therapeutics is .

When does Lineage Cell Therapeutics pay dividends?

Lineage Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lineage Cell Therapeutics?

Lineage Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Lineage Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lineage Cell Therapeutics located?

Lineage Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lineage Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lineage Cell Therapeutics from 10/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2024.

When did Lineage Cell Therapeutics pay the last dividend?

The last dividend was paid out on 10/12/2024.

What was the dividend of Lineage Cell Therapeutics in the year 2023?

In the year 2023, Lineage Cell Therapeutics distributed 0 USD as dividends.

In which currency does Lineage Cell Therapeutics pay out the dividend?

The dividends of Lineage Cell Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Lineage Cell Therapeutics

Our stock analysis for Lineage Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lineage Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.